Clinical trials: Hereditary Breast Carcinoma

Advanced Breast Cancer

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

• Completed
• Age: 18 years and older
• Phase 3
• Results posted

The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.

Trial name

MONALEESA-3 (NCT02422615)

Testing

Ribociclib, Fulvestrant

Where

174 sites in United States, Australia and 28 more

Volunteers

726 people

Sponsor

Novartis Pharmaceuticals